“For three years – that’s how long this wonder drug has been in shortage – they’ve been compounding copies of semaglutide injection for patients at a time when Novo Nordisk could not ...

Novo Nordisk wants the Food and Drug Administration (FDA ... plans don’t widely cover the drugs for weight loss purposes. Semaglutide, the active ingredient in both, has been in shortage ...

April 14 (Reuters) - Danish drugmaker Novo Nordisk ... known as semaglutide, has given rise to concerns about unregulated, compounded and counterfeit medicines. Its weight-loss drug Wegovy also ...

Hims & Hers started prescribing compounded semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy ... a specific ingredient in a branded drug. But drugmakers and some health ...

Shares of Novo Nordisk slipped in Monday morning ... 61.9% of patients were given the highest dose of the drug, which combines the GLP-1 agonist semaglutide, the active ingredient in Wegovy ...